ENSG00000134371


Homo sapiens

Features
Gene ID: ENSG00000134371
  
Biological name :CDC73
  
Synonyms : CDC73 / cell division cycle 73 / Q6P1J9
  
Possible biological names infered from orthology :
  
Species: Homo sapiens
  
Chr. number: 1
Strand: 1
Band: q31.2
Gene start: 193121997
Gene end: 193253901
  
Corresponding Affymetrix probe sets: 218578_at (Human Genome U133 Plus 2.0 Array)   229828_at (Human Genome U133 Plus 2.0 Array)   235196_at (Human Genome U133 Plus 2.0 Array)   
  
Cross references: Ensembl peptide - ENSP00000494944
Ensembl peptide - ENSP00000496633
Ensembl peptide - ENSP00000356405
Ensembl peptide - ENSP00000490035
NCBI entrez gene - 79577     See in Manteia.
OMIM - 607393
RefSeq - NM_024529
RefSeq - XM_006711537
RefSeq Peptide - NP_078805
swissprot - A0A1B0GUB2
swissprot - Q6P1J9
Ensembl - ENSG00000134371
  
Related genetic diseases (OMIM): 145000 - Hyperparathyroidism, familial primary, 145000
  145001 - Hyperparathyroidism-jaw tumor syndrome, 145001
  608266 - Parathyroid carcinoma, 608266
See expression report in BioGPS
See gene description in Wikigenes
See gene description in GeneCards
See co-cited genes in PubMed


Ortholog prediction (from Ensembl)
Ortholog nameID Species
 cdc73ENSDARG00000020201Danio rerio
 CDC73ENSGALG00000002469Gallus gallus
 Cdc73ENSMUSG00000026361Mus musculus


Paralog prediction (from Ensembl)
Paralog nameIDSimilarity(%)
No match


Protein motifs (from Interpro)
Interpro ID Name
 IPR007852  Cdc73/Parafibromin
 IPR031336  Cell division control protein 73, C-terminal
 IPR032041  Paf1 complex subunit Cdc73, N-terminal domain


Gene Ontology (GO)
TypeGO IDTermEv.Code
 biological_processGO:0000122 negative regulation of transcription by RNA polymerase II IEA
 biological_processGO:0001558 regulation of cell growth IEA
 biological_processGO:0001711 endodermal cell fate commitment IEA
 biological_processGO:0006351 transcription, DNA-templated IEA
 biological_processGO:0006355 regulation of transcription, DNA-templated IEA
 biological_processGO:0006357 regulation of transcription by RNA polymerase II IEA
 biological_processGO:0006366 transcription by RNA polymerase II TAS
 biological_processGO:0006368 transcription elongation from RNA polymerase II promoter IEA
 biological_processGO:0006378 mRNA polyadenylation IMP
 biological_processGO:0007049 cell cycle IEA
 biological_processGO:0008285 negative regulation of cell proliferation IDA
 biological_processGO:0010390 histone monoubiquitination IDA
 biological_processGO:0016055 Wnt signaling pathway IEA
 biological_processGO:0016567 protein ubiquitination TAS
 biological_processGO:0016570 histone modification IEA
 biological_processGO:0019827 stem cell population maintenance IEA
 biological_processGO:0030177 positive regulation of Wnt signaling pathway IDA
 biological_processGO:0031442 positive regulation of mRNA 3"-end processing IMP
 biological_processGO:0031648 protein destabilization IMP
 biological_processGO:0032968 positive regulation of transcription elongation from RNA polymerase II promoter IDA
 biological_processGO:0033523 histone H2B ubiquitination IDA
 biological_processGO:0034402 recruitment of 3"-end processing factors to RNA polymerase II holoenzyme complex IBA
 biological_processGO:0043066 negative regulation of apoptotic process IEA
 biological_processGO:0045638 negative regulation of myeloid cell differentiation IDA
 biological_processGO:0045944 positive regulation of transcription by RNA polymerase II IDA
 biological_processGO:0048147 negative regulation of fibroblast proliferation IMP
 biological_processGO:0050680 negative regulation of epithelial cell proliferation IMP
 biological_processGO:0071222 cellular response to lipopolysaccharide IEA
 biological_processGO:1902808 positive regulation of cell cycle G1/S phase transition IMP
 biological_processGO:1904837 beta-catenin-TCF complex assembly TAS
 biological_processGO:2000134 negative regulation of G1/S transition of mitotic cell cycle IDA
 cellular_componentGO:0000784 nuclear chromosome, telomeric region HDA
 cellular_componentGO:0005634 nucleus IDA
 cellular_componentGO:0005654 nucleoplasm TAS
 cellular_componentGO:0005829 cytosol IDA
 cellular_componentGO:0016593 Cdc73/Paf1 complex IEA
 molecular_functionGO:0000993 RNA polymerase II core binding IDA
 molecular_functionGO:0001076 transcription factor activity, RNA polymerase II transcription factor binding IBA
 molecular_functionGO:0005515 protein binding IPI


Pathways (from Reactome)
Pathway description
Formation of RNA Pol II elongation complex
Formation of the beta-catenin:TCF transactivating complex
Hedgehog on state
RNA Polymerase II Pre-transcription Events
RNA Polymerase II Transcription Elongation
E3 ubiquitin ligases ubiquitinate target proteins


Phenotype (from MGI, Zfin or HPO)
IDPhenotypeDefinition Genetic BG
 HP:0000006 Autosomal dominant inheritance "A mode of inheritance that is observed for traits related to a gene encoded on one of the autosomes (i.e., the human chromosomes 1-22) in which a trait manifests in heterozygotes. In the context of medical genetics, an autosomal dominant disorder is caused when a single copy of the mutant allele is present. Males and females are affected equally, and can both transmit the disorder with a risk of 50% for each child of inheriting the mutant allele." [HPO:curators]
Show

 HP:0000083 Renal failure 
Show

 HP:0000107 Renal cysts 
Show

 HP:0000121 Nephrocalcinosis 
Show

 HP:0000131 Uterine leiomyoma 
Show

 HP:0000787 Kidney stones 
Show

 HP:0000843 Hyperparathyroidism 
Show

 HP:0000934 Chondrocalcinosis 
Show

 HP:0000938 Osteopenia "Osteopenia refers to a reduction in bone mineral density (BMD) below normal peak BMD but not low enough to be classified as osteoporosis. According to the WHO, osteopenia is characterized by a value of BMD more than 1 standard deviation below the young adult mean, but less than 2 standard deviations below this value." [HPO:curators]
Show

 HP:0000939 Osteoporosis "Osteoporosis is a systemic skeletal disease characterized by low bone density and microarchitectural deterioration of bone tissue with a consequent increase in bone fragility. According to the WHO, osteoporosis is characterized by a value of BMD 2.5 standard deviations or more below the young adult mean." [HPO:curators]
Show

 HP:0001324 Muscle weakness "Reduced strength of muscles." [HPO:curators]
Show

 HP:0001428 Somatic mutation 
Show

 HP:0001609 Hoarse voice 
Show

 HP:0001733 Pancreatitis 
Show

 HP:0001824 Weight loss 
Show

 HP:0001959 Polydipsia 
Show

 HP:0002015 Dysphagia "Difficulty in swallowing." [HPO:curators]
Show

 HP:0002017 Nausea and vomiting 
Show

 HP:0002019 Constipation 
Show

 HP:0002148 Hypophosphatemia "A lower than normal level of blood phosphate." [HPO:curators]
Show

 HP:0002150 Hypercalciuria 
Show

 HP:0002315 Headache "Cephalgia, or pain in the head originating from the cerebral vault." [HPO:curators]
Show

 HP:0002574 Episodic abdominal pain 
Show

 HP:0002653 Bone pain 
Show

 HP:0002667 Nephroblastoma (Wilms tumor) "A kind of renal tumor primarily affecting children. It is characterized by an abnormal proliferation of the metanephric blastema cells, which are believed to be primitive embryologic cells of the kidney. Clinically, nephroblatoma usually presents as an abdominal mass, and in some cases with abdominal pain, hypertension, hematuria, and fever." [HPO:curators]
Show

 HP:0002890 Thyroid carcinoma 
Show

 HP:0002897 Parathyroid adenoma 
Show

 HP:0003072 Hypercalcemia "A level of blood calcium that is higher than normal." [HPO:curators]
Show

 HP:0003109 Hyperphosphaturia "An increased excretion of phosphates in the urine." [HPO:curators]
Show

 HP:0003165 Elevated serum parathyroid hormone (PTH) level 
Show

 HP:0004398 Peptic ulcer 
Show

 HP:0006725 Pancreatic adenocarcinoma 
Show

 HP:0006780 Parathyroid carcinoma 
Show

 HP:0008200 Primary hyperparathyroidism 
Show

 HP:0008250 Infantile hypercalcemia 
Show

 HP:0008696 Bilateral renal hamartomas 
Show

 HP:0010614 Fibroma "Benign tumors that are composed of fibrous or connective tissue. They can grow in all organs, arising from mesenchyme tissue. The term "fibroblastic" or "fibromatous" is used to describe tumors of the fibrous connective tissue. When the term fibroma is used without modifier, it is usually considered benign, with the term fibrosarcoma reserved for malignant tumors." [HPO:curators]
Show

 HP:0010788 Testicular neoplasia 
Show

 HP:0011458 Abdominal symptom 
Show

 HP:0012032 Lipoma "Benign neoplasia derived from lipoblasts or lipocytes of white or brown fat. May be angiomatous or hibernomatous." [MPATH:417]
Show

 HP:0012232 Shortened QT interval "Decreased time between the start of the Q wave and the end of the T wave as measured by the electrocardiogram (EKG)." [HPO:probinson]
Show

 HP:0012378 Fatigue "A subjective feeling of tiredness characterized by a lack of energy and motivation." [HPO:probinson]
Show

 HP:0040160 Generalized osteoporosis 
Show

 HP:0200025 mandibular pain 
Show

  


Interacting proteins (from Reactome)
Interactor ID Name Interaction type
 ENSG00000166477 LEO1 / Q8WVC0 / LEO1 homolog, Paf1/RNA polymerase II complex component  / reaction / complex
 ENSG00000138795 LEF1 / Q9UJU2 / lymphoid enhancer binding factor 1  / reaction / complex
 ENSG00000148737 Q9NQB0 / TCF7L2 / transcription factor 7 like 2  / complex / reaction
 ENSG00000106571 GLI3 / P10071 / GLI family zinc finger 3  / reaction / complex
 ENSG00000111087 GLI1 / P08151 / GLI family zinc finger 1  / reaction / complex
 ENSG00000168036 CTNNB1 / P35222 / catenin beta 1  / reaction / complex
 ENSG00000074047 GLI2 / P10070 / GLI family zinc finger 2  / complex / reaction






 

1 s.

 
External programs and data are copyrighted by and are the property of their respective authors.
The Manteia system, data and analyses are provided "as is" with no warranties, expressed or implied as to capabilities or accuracy. User assumes the entire risk as to the results and performance of the software, data and documentation


                   


© Olivier Tassy / Olivier Pourquie 2007-2024
contact: otassy@igbmc.fr